Acasti Pharma reported $18.67M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acasti Pharma USD 18.67M 1.81M Dec/2025
Addus HomeCare USD 99.57M 3.5M Jun/2026
Amarin USD 143.56M 12.5M Jun/2026
Cassava Sciences USD 86.57M 8.93M Mar/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Option Care Health USD 193.77M 16.45M Jun/2026
Organigram Holdings CAD 4.29M 3.28M Mar/2026
Tilray USD 264.83M 43.16M Jun/2025